CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors.
Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
纳米抗体因其高溶解度而非常适合用于构建生物制剂。我们制备了针对 CD38 的纳米抗体，CD38 是一种在多发性骨髓瘤和其他血液系统恶性肿瘤中过表达的肿瘤标志物。随后，我们利用这些 CD38 特异性纳米抗体构建了重链抗体、双特异性杀伤细胞衔接器（BiKEs）、嵌合抗原受体（CAR）-NK 细胞以及展示纳米抗体的 AAV 载体。在此，我们综述这些基于纳米抗体的构建体在特异性且有效靶向表达 CD38 的骨髓瘤细胞方面的应用价值。我们临床前研究的有希望结果值得进一步开展临床研究，以评估这些 CD38 特异性纳米抗体构建体用于治疗多发性骨髓瘤的潜力。
Nanobodies are well suited for constructing biologics due to their high solubility.
We generated nanobodies directed against CD38, a tumor marker that is overexpressed by multiple myeloma and other hematological malignancies.
We then used these CD38-specific nanobodies to construct heavy chain antibodies, bispecific killer cell engagers (BiKEs), chimeric antigen receptor (CAR)-NK cells, and nanobody-displaying AAV vectors.
Here we review the utility of these nanobody-based constructs to specifically and effectively target CD38-expressing myeloma cells. The promising results of our preclinical studies warrant further clinical studies to evaluate the potential of these CD38-specific nanobody-based constructs for treatment of multiple myeloma.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
